

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Healthia Limited
ABN	85 626 087 223

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mrs Lisa Michelle Roach
Date of last notice	2 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<ol style="list-style-type: none">1. Indirect2. Indirect3. Direct4. Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none">1. Matthew John Roach as trustee for The Roach Business Trust. Lisa Roach is the Principal and Primary Beneficiary of this trust.2. Roach Super (QLD) Pty Ltd as trustee for the Roach Super Fund. Lisa Roach is a director and shareholder of the trustee and a member of the Superannuation Fund.3. Lisa Michelle Roach4. Lisa Michelle Roach
Date of change	<ol style="list-style-type: none">1. Not applicable2. Not applicable3. Not applicable4. 29 November 2022
No. of securities held prior to change	<ol style="list-style-type: none">1. 625,0712. 248,0553. 124,3684. 156,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	<ol style="list-style-type: none"> 1. Ordinary Shares 2. Ordinary Shares 3. Ordinary Shares 4. Performance Rights – each being a conditional entitlement to one ordinary share in the Company in accordance with the Company's Performance Rights Plan.
Number acquired	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil 4. (a) 201,469 FY23 Performance Rights (b) 94,853 Retention Performance Rights
Number disposed	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil 4. Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil 4. Performance rights form part of Directors' remuneration and are issued for nil consideration.
No. of securities held after change	<ol style="list-style-type: none"> 1. 625,071 2. 248,055 3. 124,368 4. 452,322
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> 1. Not applicable 2. Not applicable 3. Not applicable 4. (a) Security holder approval was obtained at Healthia's Annual General Meeting on 29 November 2022 (the AGM) to issue 2023 Performance Rights to Directors pursuant to the Company's Performance Rights Plan (the Plan), which was approved by shareholders at the AGM. (b) Security holder approval was obtained at the AGM to issue Retention Performance Rights to Directors pursuant to the Plan, which was approved by shareholders at the AGM.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.